10:14 AM EDT, 07/03/2024 (MT Newswires) -- Insmed ( INSM ) is scheduled to disclose additional positive results from a phase 3 trial of its brensocatib drug candidate in patients with non-cystic fibrosis bronchiectasis on Thursday at a medical conference in Dundee, Scotland, it said.

The company will present data at the World Bronchiectasis Conference showing patients in 10- and 25-milligram dosage groups both experienced improved quality of life from baseline levels in a measure of their respiratory symptoms. Brensocatib also was well-tolerated and demonstrated a favorable safety profile, Insmed ( INSM ) said.

Insmed ( INSM ) previously said both the 10- and 25-milligram dosages of brensocatib met the primary endpoint of the late-stage trial of a statistically and clinically significant reduction in the annualized rate of pulmonary exacerbations, with patients in the 10-milligram group experiencing a 21.1% drop in risk compared with a placebo over the 52-week treatment period and a 19.4% risk reduction in the 25-milligram group.

Both dosage strengths met several secondary endpoints, including significantly prolonging the time to first exacerbation and significantly increasing the odds of remaining exacerbation-free over the treatment period, according to Insmed ( INSM ), which is expecting to file a new drug application for brensocatib with US regulators during the final three months of 2024.

Price: 64.39, Change: -0.11, Percent Change: -0.17